BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Rhea-AI Summary
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced the U.S. FDA has granted Fast Track designation to BBO-11818 for treating adult patients with advanced KRAS-mutant pancreatic ductal adenocarcinoma on April 20, 2026.
BBO-11818 is a pan-KRAS inhibitor in a Phase 1 trial (KONQUER-101); preliminary January 2026 data showed a confirmed partial response in pancreatic cancer and dose-dependent tumor reductions. Updated Phase 1 data expected in the second half of 2026.
Positive
- FDA Fast Track designation for BBO-11818 (KRAS-mutant pancreatic cancer)
- Confirmed partial response in pancreatic cancer in January 2026 data
- Observed anti-tumor activity across dose levels in Phase 1
Negative
- BBO-11818 remains in Phase 1—efficacy and safety not yet established
- Updated clinical data not expected until second half of 2026
News Market Reaction – BBOT
In the Apr 21 session, BBOT gained 2.16%, reflecting a moderate positive market reaction. Argus tracked a peak move of +11.8% during that session. Argus tracked a trough of -3.9% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 07 | Phase 1 data update | Positive | +4.4% | Preliminary Phase 1 data across three RAS/PI3Kα programs with strong efficacy signals. |
| Oct 25 | Preclinical combo data | Positive | +3.2% | Preclinical data for BBO-10203 showing KRAS-mutant tumor growth inhibition and combo benefits. |
| Oct 23 | Preclinical BBO-11818 data | Positive | +0.8% | Preclinical results demonstrating potent pan‑KRAS inhibition and tumor regressions for BBO-11818. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical and preclinical RAS-pathway updates have historically been followed by modestly positive price reactions.
Over the past year, BBOT has consistently reported progress across its KRAS and PI3Kα pipeline. Prior clinical‑trial‑tagged updates highlighted early Phase 1 efficacy signals for BBO-11818 and preclinical and early clinical data for BBO-10203, with price reactions between 0.83% and 4.36%. These announcements, including a 65% ORR and 66% 6‑month PFS in KRASG12C NSCLC and a 56% tumor reduction in pancreatic cancer, frame today’s Fast Track designation as part of an ongoing clinical de‑risking trajectory for BBO‑11818.
Key Terms
fast track designation regulatory
phase 1 medical
pan-kras inhibitor medical
kras-mutant medical
partial response medical
objective response rate medical
progression-free survival medical
restricted stock units financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors
Updated Phase 1 clinical data are expected in the second half of 2026
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BBO-11818 for the treatment of adult patients with advanced KRAS-mutant pancreatic ductal adenocarcinoma.
"Receiving Fast Track designation from the FDA for BBO-11818 in KRAS-mutant pancreatic ductal adenocarcinoma reflects the importance and urgency of accelerating the development of our pan-KRAS inhibitor in this serious disease," said Yong Ben, MD, Chief Medical and Development Officer of BBOT. "Pancreatic cancer remains one of the most difficult-to-treat malignancies. KRAS mutations are present in the vast majority of cases, yet patients have had few targeted options. This designation will help us collaborate closely with the FDA to advance BBO-11818 as efficiently as possible for patients who need new options."
This designation follows preliminary data, first released in January 2026, in which BBO-11818 monotherapy demonstrated a confirmed partial response in pancreatic cancer. In addition, anti-tumor activity was observed across dose levels and tumor types with tumor reductions at higher dose levels with a generally favorable, differentiated safety profile in dose escalation.
While KRASG12C inhibitors have demonstrated promising clinical efficacy, there remains a clear unmet medical need for therapies targeting cancers that carry other KRAS mutations, such as KRASG12D and KRASG12V. BBO-11818 was developed to address this gap and is specifically designed as a potent pan-KRAS inhibitor with strong binding affinity for KRAS, high selectivity over HRAS and NRAS, and the ability to achieve high levels of KRAS inhibition in both the ON and OFF states. BBO-11818 is being evaluated as monotherapy, in combination with standard-of-care therapies, or alongside BBOT’s RAS:PI3Kα breaker, BBO-10203.
Fast Track designation is intended to help rapidly advance the development and review process for promising therapeutic candidates for serious conditions that may fill an unmet medical need.
About BBO-11818
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS-mutant preclinical models, including KRASG12D and KRASG12V. In addition, it potently suppresses MAPK signaling and inhibits cell proliferation in KRAS-mutant cell lines. BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors.
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements in this press release that are not historical facts may be deemed forward-looking statements, which generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends. These statements are based on various assumptions, whether or not identified in this press release, and are the current expectations of BBOT’s management and are not predictions of actual performance. Many actual events and circumstances are beyond the control of BBOT. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to the timing of expected regulatory and business milestones, including interactions with regulatory authorities, the progress of enrollment in clinical trials and availability of data from ongoing and planned clinical trials; and those factors discussed in documents BBOT has filed or will file with the U.S. Securities and Exchange Commission.
In addition, forward-looking statements reflect BBOT’s expectations, plans, or forecasts of future events and views as of the date of this press release and are qualified in their entirety by reference to the cautionary statements herein. BBOT anticipates that subsequent events and developments will cause BBOT’s assessments to change. These forward-looking statements should not be relied upon as any guarantee, assurance, prediction or definitive statement of fact or probability or as representing BBOT’s assessments as of any date subsequent to the date of this press release. Neither BBOT, nor any of its affiliates undertake any obligation to update these forward-looking statements, except as required by law.
BBOT Contacts:
Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com
